Lv1
30 积分 2024-11-24 加入
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
2天前
已完结
FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
25天前
已完结
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis
1个月前
已完结
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
2个月前
已完结
CAR-T cell therapy for cancer: current challenges and future directions
4个月前
已完结
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
4个月前
已完结
Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission
5个月前
已完结
The race to reset autoimmune diseases
6个月前
已完结
Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
9个月前
已完结
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
9个月前
已完结
皖公网安备34019202002308
